Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Sarepta Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sarepta has violated federal securities laws.
Sarepta Investigation Details
On November 3, 2025, Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), both aimed at treating Duchenne muscular dystrophy, “did not meet statistical significance on its primary endpoint”. Following this news, Sarepta’s stock price fell $8.25 per share, or 33.74%, to close at $16.20 per share on November 4, 2025.
What’s Next for Sarepta Investors?
If you are aware of any facts relating to this investigation or purchased Sarepta securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
SRPT — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”